LA JOLLA, CA – May 12, 2025 – A groundbreaking study from the Salk Institute for Biological Studies has unveiled a critical molecular pathway that could revolutionize the treatment of metabolic dysfunction and muscle fatigue. Researchers have identified estrogen-related receptors (ERRs) as indispensable drivers of mitochondrial growth and activity in muscle cells, offering a potent new therapeutic target for a wide array of debilitating conditions ranging from muscular dystrophy to age-related decline.
The findings, published today in the prestigious journal Proceedings of the National Academy of Sciences, suggest that developing drugs to activate these receptors could restore vital energy supplies in millions of people afflicted by metabolic disorders, muscle weakness, and chronic fatigue. This discovery represents a significant leap forward in our understanding of cellular energy regulation and opens unprecedented avenues for intervention.
Breakthrough in Metabolic Repair
At the core of human health lies cellular metabolism, the intricate process by which our bodies convert the food we eat into usable energy. This vital function is powered by tiny, bean-shaped organelles called mitochondria, often referred to as the "powerhouses of the cell." They are particularly crucial in muscle cells, which demand vast amounts of energy to facilitate movement, exercise, and indeed, every physical action we undertake.
However, mitochondrial dysfunction is a pervasive and often devastating problem. Globally, approximately 1 in 5,000 individuals are born with inherited mitochondrial disorders, leading to severe and chronic health issues. Beyond these genetic predispositions, a much larger population develops metabolic dysfunction later in life, a condition strongly associated with aging and a host of chronic diseases including cancer, multiple sclerosis (MS), heart disease, and neurodegenerative conditions like dementia. The impact of impaired mitochondrial function manifests as profound muscle weakness, debilitating fatigue, and a reduced quality of life.
Despite its widespread impact, effective treatments for mitochondrial dysfunction have remained elusive. This new research from the Salk Institute, however, offers a beacon of hope. The study pinpoints a group of proteins known as estrogen-related receptors (ERRs) as a novel and highly promising therapeutic target. The Salk scientists meticulously demonstrated that ERRs play a pivotal role in regulating muscle cell metabolism, especially during periods of increased energy demand, such as exercise. When muscles require more fuel, ERRs possess the remarkable ability to orchestrate an increase in both the number and energetic output of mitochondria within these critical cells.
"Estrogen-related receptors look a lot like classic estrogen receptors, but their function has been much less understood," explains senior author Ronald Evans, a professor and the March of Dimes Chair in Molecular and Developmental Biology at Salk. Evans, a towering figure in molecular biology, first discovered these receptors in 1988, marking an early recognition of their involvement in energy metabolism. "Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction."
The implications of this finding are profound. By identifying a mechanism that can directly enhance mitochondrial function and energy production, the Salk team has laid the groundwork for the development of drugs that could effectively restore energy supplies in patients suffering from a wide spectrum of metabolic disorders, including devastating conditions like muscular dystrophy, for which current treatments are largely symptomatic.
A Decades-Long Quest for Understanding
The current breakthrough is not an isolated discovery but rather the culmination of decades of pioneering research, tracing its origins back to a fundamental scientific inquiry into how our bodies regulate gene expression and respond to hormones.
The Genesis of Nuclear Hormone Receptors
The story begins in the 1980s with Ronald Evans’ landmark discovery of a novel family of proteins he aptly named "nuclear hormone receptors." This monumental achievement reshaped our understanding of cellular signaling. Evans and his team revealed that these receptors act as molecular switches, attaching themselves directly to our DNA and, in response to specific hormones, controlling which genes are turned "on" or "off." This intricate regulatory system governs a vast array of physiological processes, from development and reproduction to metabolism and immunity.
Estrogen-related receptors (ERRs) emerged as a distinct branch within this expansive family of nuclear hormone receptors. While structurally similar to classic estrogen receptors, ERRs function independently of estrogen, indicating a unique and specialized role within the cell. Evans’ lab was among the first to recognize their involvement in energy metabolism as early as 1988, sparking a long-term interest in their precise functions.
Connecting ERRs to High-Energy Organs
Early investigations into ERRs revealed their preferential expression in organs characterized by high energy demands, such as the heart and the brain. This distribution naturally led Evans’ team to hypothesize a significant role for ERRs in regulating metabolism within another notoriously high-energy organ: skeletal muscle. Muscles, after all, are the engines of movement, requiring an enormous and adaptable supply of fuel.
One of the most potent stimuli for increasing mitochondrial numbers and efficiency in muscle cells is exercise, a process known as mitochondrial biogenesis. Regular physical activity signals muscle cells to create more mitochondria, thereby enhancing their capacity to produce energy. However, this creates a significant challenge for individuals grappling with muscular and metabolic disorders. For these patients, exercise is often excruciatingly difficult, if not impossible, due trapping them in a vicious cycle of weakness and fatigue. This critical limitation spurred scientists to search for alternative, pharmacological methods to stimulate mitochondrial biogenesis, aiming to confer the benefits of exercise without the physical exertion.
"Mitochondria are our cells’ energy factories, so the more we exercise, the more mitochondria our muscles need," says first author Weiwei Fan, a staff scientist in Evans’ lab. "This got us thinking — if we could understand how exercise induces mitochondrial biogenesis, we might be able to target those same mechanisms pharmacologically to trigger this process in people who are too weak to exercise." This compelling question formed the bedrock of their current investigation.
Unraveling the ERR Mechanism
To definitively ascertain the role of estrogen-related receptors in muscle cell metabolism, Fan and his colleagues embarked on a meticulously designed experimental journey using mouse models. Their strategy involved selectively deleting three different forms of ERRs – alpha (ERRα), beta (ERRβ), and gamma (ERRγ) – within the muscle tissues of the mice, and then carefully observing the resulting physiological and molecular effects.
Their initial observations revealed intriguing insights into the hierarchy and redundancy of these receptors. They found that ERRα was the most abundant type of receptor in muscle tissue. However, surprisingly, the loss of ERRα alone had only mild impacts on muscle tissue under normal, sedentary conditions. This suggested a compensatory mechanism at play. Further investigation confirmed this: the researchers discovered that ERRγ, despite making up only a small fraction (approximately 4%) of total estrogen-related receptors, was capable of compensating for the loss of ERRα under typical conditions, maintaining a baseline level of mitochondrial function.
The true significance of ERRs became starkly apparent when the researchers deleted both ERRα and ERRγ simultaneously. This dual deletion led to severe impairments in muscle mitochondrial activity, profoundly affecting their shape, size, and overall function. This critical finding underscored that while ERRγ could compensate under normal conditions, the combined action of these receptors was essential for robust mitochondrial health.
The team then turned their attention to the role of ERRα in the context of exercise, hypothesizing that its high abundance might be crucial for adaptation to physical stress. They had their mice engage in exercise on mechanical running wheels, a standard method for inducing mitochondrial biogenesis. This experiment proved to be a pivotal moment in their research. It unequivocally revealed that the loss of ERRα alone could entirely block exercise-induced mitochondrial biogenesis, demonstrating its indispensable role in the muscle’s adaptive response to physical activity.
Prior research had established that exercise-induced mitochondrial growth was largely driven by another protein known as PGC1α, often lauded as the "master regulator" of mitochondria throughout the body. However, PGC1α presents a significant challenge for therapeutic drug development: unlike nuclear hormone receptors such as ERRs, PGC1α cannot bind directly to genes. Instead, it relies on partner proteins to execute its regulatory functions, making it a more difficult target for direct pharmacological manipulation.
This distinction proved critical. When Evans’ lab examined the muscle cells after exercise, they discovered a crucial partnership: PGC1α was indeed collaborating with ERRα to drive mitochondrial biogenesis. But critically, ERRα, unlike PGC1α, possesses the ability to bind directly to the DNA sequences of mitochondrial energetic genes and turn them "on." This direct action positions ERRα as a far more accessible and promising target for developing therapeutic drugs aimed at improving muscle’s mitochondrial performance and overall energy output.
Supporting Data: The Science Behind the Promise
The Salk Institute’s rigorous scientific approach underpins the compelling promise of this discovery. The study’s methodology, the depth of its findings, and the established expertise of its authors lend significant weight to its conclusions.
Mitochondria: The Cell’s Powerhouses
To fully appreciate the study’s impact, one must understand the fundamental role of mitochondria. These organelles are the primary sites of cellular respiration, the metabolic pathway that generates adenosine triphosphate (ATP), the universal energy currency of the cell. Without sufficient, functional mitochondria, cells, particularly those with high energy demands like muscle cells, cannot operate efficiently.
Dysfunctional mitochondria manifest in a spectrum of problems. At the cellular level, impaired mitochondria produce less ATP, leading to energy deficits. They can also generate harmful reactive oxygen species (ROS), contributing to oxidative stress and cellular damage. At the organismal level, these cellular deficiencies translate into profound muscle weakness (myopathy), persistent fatigue, exercise intolerance, and a cascade of systemic issues affecting nearly every organ system. The fact that 1 in 5,000 individuals are born with these severe dysfunctions, and countless others acquire them through aging or disease, underscores the immense public health burden.
The Role of Estrogen-Related Receptors (ERRs)
The study provides an intricate look into how ERRs orchestrate metabolic repair. While ERRs share structural similarities with classic estrogen receptors, their functional independence from estrogen hormones is key. The Salk research focused on the three isoforms: ERRα, ERRβ, and ERRγ. They found that ERRα is the dominant isoform in muscle, but ERRγ plays a crucial compensatory role under normal conditions.
The mechanism by which ERRs act is elegant and direct. When activated, ERRs bind to specific DNA sequences within the nucleus of muscle cells. These sequences are typically located in the promoter regions of genes that encode proteins essential for mitochondrial function and biogenesis. By binding to these regions, ERRs effectively "turn on" these genes, leading to increased production of mitochondrial components. This results in an increase in both the number of mitochondria within the cell and an enhancement of their individual capacity to produce energy, thereby boosting the overall energetic output of the muscle. This process, known as mitochondrial biogenesis, is the body’s natural way of adapting to increased energy demands, such as those imposed by exercise. The Salk study reveals ERRs as the critical molecular conduit for this adaptation.
Experimental Rigor and Findings
The strength of the Salk study lies in its precise genetic manipulation and physiological testing. By creating mouse models with specific ERR deletions in muscle tissue, the researchers could isolate the contribution of each receptor isoform. The finding that deleting ERRα alone had only mild effects initially, but that deleting both ERRα and ERRγ led to severe mitochondrial impairment, highlights a nuanced regulatory network where redundancy ensures baseline function, but comprehensive action is required for optimal performance.
The exercise wheel experiment was particularly illuminating. It provided a direct physiological context for ERRα’s importance. The complete blockage of exercise-induced mitochondrial biogenesis upon ERRα deletion unequivocally demonstrated its indispensable role in the muscle’s adaptive response to physical stress. This finding is critical because it suggests that activating ERRα could potentially mimic the beneficial effects of exercise at a molecular level, offering a therapeutic strategy for those unable to perform physical activity.
Furthermore, the study elegantly clarified the relationship between ERRα and PGC1α. While PGC1α is a master regulator, its indirect action makes it a challenging drug target. The discovery that PGC1α partners with ERRα, and that ERRα then directly binds to mitochondrial energetic genes, positions ERRα as the more "druggable" target. This direct gene-binding capability is what makes ERRα so appealing for pharmacological intervention, as it offers a clear and specific pathway for drug design.
The extensive list of authors and supporting institutions, including the National Institutes of Health, the Department of the Navy, and various foundations, further attests to the collaborative and well-resourced nature of this significant research.
Voices from the Salk Institute
The scientific community, particularly at the Salk Institute, views these findings with considerable excitement and optimism for their potential to translate into tangible clinical benefits.
Senior Author, Ronald Evans
Professor Ronald Evans, a titan in the field of molecular biology, articulates the profound significance of this discovery, framing it within the context of his long-standing work on nuclear hormone receptors. His initial discovery of these receptors decades ago laid the fundamental groundwork for understanding how hormones regulate gene expression. His continued exploration of ERRs, which he first identified in 1988, underscores a sustained commitment to unraveling complex biological mechanisms.
"Our lab’s journey with estrogen-related receptors has been one of persistent curiosity and scientific rigor," Evans reflects. "To now identify them as such indispensable drivers of mitochondrial health and function in muscle is truly rewarding. It means we’re not just observing a phenomenon; we’re pinpointing a direct, actionable mechanism. The fact that ERRα can directly switch on the genes responsible for mitochondrial performance makes it an incredibly attractive target for therapeutic development. We’re talking about potentially reversing a core deficit in many diseases, not just managing symptoms." His emphasis on "indispensable" highlights the non-negotiable role ERRs play in this vital cellular process.
First Author, Weiwei Fan
Weiwei Fan, the study’s first author, provides a more granular perspective, highlighting the practical implications for patient care. His analogy of mitochondria as "energy factories" makes the concept accessible, while his vision for pharmacological intervention speaks directly to the unmet needs of patients.
"The human body is an amazing machine, and its ability to adapt, especially through exercise, is inspiring," Fan states. "But for many, that natural adaptive mechanism is broken or inaccessible. Our goal was to understand how exercise triggers this mitochondrial growth, so we could essentially bottle that effect. Identifying ERRα as the crucial link allows us to envision a future where we can pharmacologically trigger this essential process, restoring muscle strength and combating fatigue in individuals who are too frail or ill to exercise."
Fan further emphasizes the potential for broad systemic benefits, underscoring that improving mitochondrial function in muscles is unlikely to be an isolated effect. "Our findings suggest that activating estrogen-related receptors could not only help fuel people’s muscles, but it could also have other beneficial effects across the whole body," he adds. "Improving mitochondrial function and energy metabolism could help strengthen many different organ systems, including the brain and heart. This isn’t just about muscle; it’s about systemic vitality." This holistic perspective suggests a far-reaching impact beyond localized muscle pathology.
Paving the Way for New Therapies
The Salk Institute’s discovery of the pivotal role of estrogen-related receptors in mitochondrial biogenesis and energy metabolism represents more than just a scientific curiosity; it signifies a critical turning point in the quest for novel therapies for a wide spectrum of debilitating diseases.
Addressing a Spectrum of Diseases
The implications for patient populations are vast. Conditions characterized by muscle weakness and fatigue are notoriously difficult to treat, often lacking disease-modifying therapies that target the underlying cause.
- Muscular Dystrophy: For patients with muscular dystrophies, progressive muscle degeneration leads to severe weakness and loss of function. Restoring mitochondrial health could slow disease progression and improve muscle endurance.
- Aging-Related Decline: Sarcopenia, the age-related loss of muscle mass and strength, is a major public health concern. Activating ERRs could combat this decline, promoting healthier aging and greater independence for the elderly.
- Cancer Cachexia: Many cancer patients experience severe muscle wasting and fatigue (cachexia), which significantly impacts their quality of life and treatment outcomes. ERR activators could potentially mitigate this debilitating side effect.
- Multiple Sclerosis (MS) Fatigue: Chronic fatigue is one of the most disabling symptoms for individuals with MS. By enhancing mitochondrial function, a targeted therapy could alleviate this pervasive fatigue.
- Heart Failure: The heart is a muscle that relies heavily on mitochondria for its continuous pumping action. Improving cardiac mitochondrial function could offer new strategies for treating various forms of heart disease.
- Neurodegenerative Diseases (Dementia): While the study focused on muscle, Fan’s insights regarding systemic benefits point to potential applications in neurodegenerative conditions where mitochondrial dysfunction in brain cells is increasingly recognized as a contributing factor. Improving energy metabolism in the brain could hold promise for cognitive health.
Current treatments for many of these conditions are often symptomatic, focusing on managing pain, improving mobility through physical therapy, or slowing progression with limited efficacy. A therapy that directly addresses the root cause – dysfunctional energy metabolism – would represent a paradigm shift.
The Promise of Targeted Drug Development
The direct action of ERRα in binding to DNA and activating mitochondrial genes makes it an exceptionally "druggable" target. Unlike proteins like PGC1α, which require intermediaries, ERRα offers a clear and specific molecular handle for pharmaceutical intervention. This opens the door for the development of small molecule activators that could specifically enhance ERRα activity in muscle cells.
The drug development process is, of course, lengthy and complex, involving extensive preclinical testing for efficacy and safety, followed by multiple phases of clinical trials in humans. However, the clarity of the target and mechanism provides a strong foundation for this translational research. The Salk team’s work provides a compelling rationale for pharmaceutical companies to invest in developing ERR-activating compounds. Careful consideration will be given to potential off-target effects and optimal dosing, ensuring that any future therapeutic is both effective and safe.
Beyond Muscle: Systemic Benefits
The vision articulated by Weiwei Fan—that improving mitochondrial function and energy metabolism could have beneficial effects "across the whole body"—is particularly exciting. Metabolic health is intrinsically linked across organ systems. Enhanced mitochondrial function in muscles could lead to improved glucose metabolism, reduced inflammation, and better cardiovascular health. Given the high energy demands of the brain, ERR activation could theoretically offer neuroprotective benefits, though this would require significant further investigation. This interconnectedness suggests that a therapy targeting ERRs could offer broad-spectrum health improvements, enhancing overall vitality and resilience.
Future Directions
The journey from groundbreaking discovery to clinical application is a long one, but the Salk Institute’s findings provide a robust roadmap. Future research will undoubtedly delve deeper into the specific functions and regulatory mechanisms of both alpha- and gamma-type ERRs. Understanding the precise interplay between these isoforms could reveal additional therapeutic targets or strategies for maximizing efficacy.
The immediate next steps will likely involve preclinical studies to identify and optimize potential drug candidates that selectively activate ERRs. This will entail extensive in vitro (cell culture) and in vivo (animal model) testing to confirm safety, determine optimal dosages, and further validate the therapeutic potential across various disease models. If these studies prove successful, the path would then lead to human clinical trials, where the true impact on patients can be assessed.
The Salk Institute’s work on estrogen-related receptors stands as a testament to the power of fundamental scientific inquiry to unlock solutions for some of humanity’s most pressing health challenges. By illuminating an "indispensable driver" of cellular energy, this research offers a profound sense of hope for those yearning for relief from the debilitating grip of metabolic dysfunction and muscle fatigue.
Other authors include: Hui Wang, Lillian Crossley, Mingxiao He, Hunter Robbins, Chandra Koopari, Yang Dai, Morgan Truitt, Ruth Yu, Annette Atkins, and Michael Downes of Salk; Tae Gyu Oh of Salk and the University of Oklahoma; and Christopher Liddle of the University of Sydney, Australia.
The work was supported by: The National Institutes of Health (P01HL147835, DK057978, DK120515, 1R21OD030076, CCSG P30CA23100, CCSG P30 CA014195, CCSG P30 CA014195, P30 AG068635), Department of the Navy (N00014-16-1-3159), Larry L. Hillblom Foundation, Inc. (2021-D-001-NET), Wu Tsai Human Performance Alliance, Henry L. Guenther Foundation, and Waitt Foundation.
About the Author
